Share

|

|

|

Sotorasib demonstrates potential for KRAS-mutated pancreatic cancer

The KRAS G12C inhibitor sotorasib has shown “promising anticancer activity” in a phase 1/2 trial of patients with heavily pretreated, metastatic pancreatic cancer harbouring the target mutation, researchers report in The New England Journal of Medicine.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

CT brain cancer risk quantified for children and young adults

The European EPI-CT study has confirmed there is a linear dose–response relationship between radiation exposure during computed tomography imaging and the risk of malignant brain tumours, in children and young adults.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Analysis points to FOLFIRINOX chemotherapy benefits for metastatic pancreatic cancer

FOLFIRINOX chemotherapy may offer better survival than gemcitabine plus nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma, suggests a comparative effectiveness study published in JAMA Network Open.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.